Belite Bio (BLTE) EBT (2022 - 2026)

Belite Bio's EBT history runs 5 years deep, the most recent figure standing at -$26.9 million for Q1 2026.

• In Q1 2026, EBT fell 88.68% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.4 billion (down 123.99% YoY), while the FY2025 annual figure was -$77.6 million, down 132.3% from the prior year.
• EBT for Q1 2026 stood at -$26.9 million, up from -$25.3 billion in the prior quarter.
• The five-year high for EBT was -$6.8 million in Q4 2022, with the low at -$25.3 billion in Q4 2025.
• The 5-year median for EBT is -$6.8 billion (2023), against an average of -$7.4 billion.
• The sharpest annual moves came in 2024 and 2025: EBT plunged 144371.46% in 2024, then soared 99.82% in 2025.
• Belite Bio's EBT stood at -$6.8 million in 2022, then retreated by 3.07% to -$7.0 million in 2023, then slumped by 144371.46% to -$10.1 billion in 2024, then plunged by 150.73% to -$25.3 billion in 2025, then soared by 99.89% to -$26.9 million in 2026.
• Business Quant data shows BLTE's EBT at -$26.9 million in Q1 2026, -$25.3 billion in Q4 2025, and -$21.7 billion in Q3 2025.